Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 12/20 | 0.39 |
| ▸ | HTR2A | P28223 | 12/20 | 0.39 |
| ▸ | DRD3 | P35462 | 12/20 | 0.39 |
| ▸ | EED | O75530 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24326967 | 0.81 | MAPT (0.49) | ABCG2MGAMAMY1AGAASI | |
| SCHEMBL28784844 | 0.79 | MGAM (0.44) | ABCG2MGAMAMY1AGAASI | |
| SCHEMBL18400742 | 0.78 | EED (0.36) | MGAMAMY1AGAASIMGAM2 | |
| SCHEMBL27538006 | 0.78 | TSHR (0.38) | — | |
| SCHEMBL13584700 | 0.76 | ABCG2 (0.46) | ABCG2MGAMAMY1AGAASI | |
| Methylamine SCHEMBL27464902 | 0.74 | MGAM (0.49) | MGAMAMY1AGAASIMGAM2 | |
| SCHEMBL8485225 | 0.74 | ABCG2 (0.40) | ABCG2MGAMAMY1AGAASI | |
| SCHEMBL8485229 | 0.74 | MGAM (0.43) | ABCG2MGAMAMY1AGAASI | |
| SCHEMBL31546199 | 0.74 | MGAM (0.43) | ABCG2MGAMAMY1AGAASI | |
| SCHEMBL31546138 | 0.72 | MGAM (0.39) | MGAMAMY1AGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299395-B1 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | UPJOHN CO (US) | 2004-09-15 | — | — | EP | disclosed |
| US-6673793-B2 | N-(4-CHLOROBENZYL)-9-(MORPHOLIN-4-YLMETHYL)-7-OXO-2-(S)-PYRIDIN-2-YL-2,3-DIHYDRO-7H-(1,4) OXAZINO(2,3,4-IJ)QUINOLINE-6-CARBOXAMIDE, FOR EXAMPLE; INHIBITING A VIRAL DNA POLYMERASE; TREATING VIRUSES OF HERPES FAMILY | PHARMACIA & UPJOHN CO. | 2004-01-06 | — | — | US | disclosed |
| EP-1299395-A1 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20020103170-A1 | Oxazinoquinolones useful for the treatment of viral infections | PHARMACIA & UPJOHN COMPANY | 2002-08-01 | — | — | US | disclosed |
| WO-2002004462-A1 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103170-A1 | Oxazinoquinolones useful for the treatment of viral infections | ZC3HAV1, RPL5, ZC3HAV1L | ABCG2 2904/4885MGAM 2592/4885AMY1A 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.